US 11,701,405 B2
Chimeric antigen receptors and methods for reducing toxicity
Xiuli Wang, Temple City, CA (US); Stephen J. Forman, Duarte, CA (US); Lawrence Stern, Duarte, CA (US); Christine E. Brown, Duarte, CA (US); and Joseph Cohen, Duarte, CA (US)
Assigned to City of Hope, Duarte, CA (US)
Appl. No. 16/964,471
Filed by City of Hope, Duarte, CA (US)
PCT Filed Jan. 25, 2019, PCT No. PCT/US2019/015252
§ 371(c)(1), (2) Date Jul. 23, 2020,
PCT Pub. No. WO2019/148006, PCT Pub. Date Aug. 1, 2019.
Claims priority of provisional application 62/622,583, filed on Jan. 26, 2018.
Prior Publication US 2021/0046155 A1, Feb. 18, 2021
Int. Cl. A61K 38/17 (2006.01); A61K 35/17 (2015.01); C07K 16/18 (2006.01); C12N 15/86 (2006.01)
CPC A61K 38/177 (2013.01) [A61K 35/17 (2013.01); C07K 16/18 (2013.01); C12N 15/86 (2013.01); C07K 2317/622 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A nucleic acid molecule comprising: (a) a nucleotide sequence encoding a chimeric antigen receptor (CAR) comprising amino acids 23 to 665 of SEQ ID NO: 31 and (b) a nucleotide sequence encoding a protease sensitive scFv comprising, from amino to carboxy terminus, a VH domain comprising SEQ ID NO: 33 and a VL domain SEQ ID NO:34 joined by a protease-sensitive linker that is sensitive to MMP-2 or MMP-9.